Sanchez Erasmo had been dealing with AKN for 10 years. In this short video, the contrast is immediate: a longstanding affected area at the back of the scalp is followed by a later view in which that raised area is no longer visible. “What does a 10-year-old AKN look like?”
Jose Patricio lived with AKN for years. This short video compresses that long struggle into a simple message of persistence and transformation. “He’s fought for years.” Those opening words establish the scale of Jose Patricio’s experience with acne keloidalis nuchae. The supplied materials describe years of living with AKN before
At age 26, this patient was worried about hair loss. The supplied comparison images revisit his hair 20 years later, at age 46. Hair loss was already a concern for this patient at 26. The story is framed simply: “26 → 46.” Twenty years later, it describes him as having
For this patient, a previous surgical recovery had set a difficult expectation. His experience with Dr. Sanusi Umar felt very different, from his initial concern about local anesthesia to an outcome he says was better than expected. Recovery was the part this patient remembered most clearly from earlier surgery. He
What began as a small bump gradually became a much larger concern for this patient. After roughly two and a half years and previous treatment that did not work, the short video captures his account and a striking visual turning point. The patient remembers the beginning clearly. What he describes
Folliculitis decalvans (FD) presents a significant challenge in dermatology, causing localized scarring alopecia and chronic inflammation. Despite its debilitating impact, there has been a lack of effective treatment options, and the existing modalities often provide only temporary relief. In the pursuit of addressing this unmet need, our recent case series
Hair loss is a common concern affecting millions of people worldwide. The impact on an individual’s self-esteem and confidence can be significant whether genetics, hormonal imbalances, stress, or certain medical conditions cause it. While various treatment options have emerged, low-level light therapy (LLLT) has gained attention as a non-invasive and
Daxxify is the newest neurotoxin injectable approved by the FDA. Some prominent names in the family of neurotoxins are Botox, Dysport, Xeomin, and Jeuveau. These injectables aim to reduce the appearance of wrinkles, treat jowls, alter the facial structure in one way or another, or even treat hair loss. These
